These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 21802198)

  • 1. Should we stop using botulinum neurotoxin type a in patients with neurogenic detrusor overactivity after development of secondary resistance?
    Pistolesi D; Giannarini G; Stampacchia G; Selli C
    Eur Urol; 2011 Oct; 60(4):872-3. PubMed ID: 21802198
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
    Mouttalib S; Khan S; Castel-Lacanal E; Guillotreau J; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
    BJU Int; 2010 Dec; 106(11):1677-80. PubMed ID: 20590550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
    Harris MA; Harding C; Fulford S; Whiteway J
    BJU Int; 2011 Apr; 107(7):1165; author reply 1165. PubMed ID: 21438980
    [No Abstract]   [Full Text] [Related]  

  • 4. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder.
    Ellsworth P; Travis M
    Urol Nurs; 2014; 34(4):165-71. PubMed ID: 25233617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
    Cruz F; Nitti V
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
    Herschorn S; Gajewski J; Ethans K; Corcos J; Carlson K; Bailly G; Bard R; Valiquette L; Baverstock R; Carr L; Radomski S
    J Urol; 2011 Jun; 185(6):2229-35. PubMed ID: 21497851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial Comment: Solifenacin treatment after intradetrusor injections with botulinum toxin in patients with neurogenic detrusor overactivity.
    Averbeck MA
    Int Braz J Urol; 2022; 48(6):988-989. PubMed ID: 36173410
    [No Abstract]   [Full Text] [Related]  

  • 8. Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial.
    Abdel-Meguid TA
    J Urol; 2010 Dec; 184(6):2423-8. PubMed ID: 20952003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tips and Tricks in Intra-Detrusor Botulinum Toxin A (BoNTA) Injections.
    Corcos J; Biardeau X; Aharony S
    World J Urol; 2015 Jun; 33(6):899-901. PubMed ID: 26217823
    [No Abstract]   [Full Text] [Related]  

  • 10. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).
    Nambiar A; Lucas M
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S21-5. PubMed ID: 25042139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial Comment to Failure of botulinum toxin injection for neurogenic detrusor overactivity: Switch of toxin versus second injection of the same toxin.
    Truzzi JC
    Int J Urol; 2015 Dec; 22(12):1165-6. PubMed ID: 26768843
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration.
    Datta SN; Roosen A; Pullen A; Popat R; Rosenbaum TP; Elneil S; Dasgupta P; Fowler CJ; Apostolidis A
    J Urol; 2010 Dec; 184(6):2578-85. PubMed ID: 21030043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
    Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P
    Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis.
    Khan S; Game X; Kalsi V; Gonzales G; Panicker J; Elneil S; Apostolidis A; Hamid R; Dasgupta P; Kessler TM; Fowler CJ
    J Urol; 2011 Apr; 185(4):1344-9. PubMed ID: 21334639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
    Mehta S; Hill D; McIntyre A; Foley N; Hsieh J; Ethans K; Teasell RW; Loh E; Welk B; Wolfe D
    Arch Phys Med Rehabil; 2013 Aug; 94(8):1473-81. PubMed ID: 23632286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis.
    Goessaert AS; Everaert KC
    Expert Rev Neurother; 2012 Jul; 12(7):763-75. PubMed ID: 22853784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial comment on: histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
    Haferkamp A
    Eur Urol; 2008 Jun; 53(6):1253. PubMed ID: 18343561
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia.
    Chen CY; Liao CH; Kuo HC
    Spinal Cord; 2011 May; 49(5):659-64. PubMed ID: 21243000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of botulinum neurotoxin on the urinary bladder: novel insights on mechanism of action.
    Vianello A; Proietti S; Giannantoni A
    Minerva Urol Nefrol; 2010 Sep; 62(3):259-71. PubMed ID: 20940695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical electromotive botulinum toxin type A administration--part II: Clinical application.
    Kajbafzadeh AM; Ahmadi H; Montaser-Kouhsari L; Sharifi-Rad L; Nejat F; Bazargan-Hejazi S
    Urology; 2011 Feb; 77(2):439-45. PubMed ID: 20800886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.